Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor

• Status: Recruiting
• Trial end date: 2024-12-20
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with Neuroendocrine Tumor

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Treatments: Octreotide

Criteria

Inclusion Criteria:

• Patients with suspected or clearly diagnosed Neuroendocrine Tumor

• signed written consent.

• Willing and able to cooperate with all projects in this study.

Exclusion Criteria:

• pregnancy;

• breastfeeding;

• any medical condition that in the opinion of the investigator may significantly interfere with study compliance.